Maravai LifeSciences (MRVI) Competitors $2.25 -0.15 (-6.25%) Closing price 04:00 PM EasternExtended Trading$2.27 +0.02 (+1.07%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. DNLI, VCEL, NAMS, AAPG, KYMR, BHVN, IBRX, HRMY, TWST, and BLTEShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Denali Therapeutics (DNLI), Vericel (VCEL), NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Biohaven (BHVN), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Denali Therapeutics Vericel NewAmsterdam Pharma Ascentage Pharma Group International Kymera Therapeutics Biohaven ImmunityBio Harmony Biosciences Twist Bioscience Belite Bio Denali Therapeutics (NASDAQ:DNLI) and Maravai LifeSciences (NASDAQ:MRVI) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Does the media prefer DNLI or MRVI? In the previous week, Maravai LifeSciences had 3 more articles in the media than Denali Therapeutics. MarketBeat recorded 11 mentions for Maravai LifeSciences and 8 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.68 beat Maravai LifeSciences' score of 0.58 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Maravai LifeSciences 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Does the MarketBeat Community believe in DNLI or MRVI? Denali Therapeutics received 407 more outperform votes than Maravai LifeSciences when rated by MarketBeat users. Likewise, 68.76% of users gave Denali Therapeutics an outperform vote while only 59.81% of users gave Maravai LifeSciences an outperform vote. CompanyUnderperformOutperformDenali TherapeuticsOutperform Votes47168.76% Underperform Votes21431.24% Maravai LifeSciencesOutperform Votes6459.81% Underperform Votes4340.19% Which has higher valuation and earnings, DNLI or MRVI? Maravai LifeSciences has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDenali Therapeutics$330.53M6.13-$145.22M-$2.67-5.22Maravai LifeSciences$241.86M2.45-$119.03M-$1.14-2.04 Which has more risk & volatility, DNLI or MRVI? Denali Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Do insiders & institutionals believe in DNLI or MRVI? 92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 0.6% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is DNLI or MRVI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -81.13%. Maravai LifeSciences' return on equity of -6.61% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Denali TherapeuticsN/A -32.94% -30.04% Maravai LifeSciences -81.13%-6.61%-3.45% Do analysts recommend DNLI or MRVI? Denali Therapeutics currently has a consensus price target of $33.71, indicating a potential upside of 141.68%. Maravai LifeSciences has a consensus price target of $6.64, indicating a potential upside of 185.54%. Given Maravai LifeSciences' higher probable upside, analysts clearly believe Maravai LifeSciences is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.06Maravai LifeSciences 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryDenali Therapeutics beats Maravai LifeSciences on 12 of the 19 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$586.99M$6.54B$5.40B$8.47BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-1.419.1226.7519.95Price / Sales2.45252.31393.46114.60Price / Cash41.7165.8538.2534.62Price / Book0.746.486.834.58Net Income-$119.03M$143.78M$3.22B$248.19M7 Day Performance17.42%4.80%5.26%2.14%1 Month Performance31.36%9.37%13.27%16.20%1 Year Performance-78.77%-1.19%17.58%7.87% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences4.0768 of 5 stars$2.25-6.3%$6.64+195.1%-78.8%$572.99M$241.86M-1.37610DNLIDenali Therapeutics4.4205 of 5 stars$14.80+3.0%$33.79+128.3%-29.0%$2.15B$330.53M-5.36430Analyst ForecastVCELVericel2.5621 of 5 stars$42.65+2.2%$60.86+42.7%-14.9%$2.14B$238.54M710.95300Positive NewsNAMSNewAmsterdam Pharma2.5174 of 5 stars$19.22+4.6%$43.00+123.7%-2.5%$2.11B$45.56M-10.224Gap UpAAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsGap UpKYMRKymera Therapeutics2.7174 of 5 stars$32.17+7.0%$55.53+72.6%-12.7%$2.09B$47.07M-13.75170Analyst ForecastGap DownBHVNBiohaven3.4882 of 5 stars$20.47+1.1%$62.54+205.5%-58.7%$2.09BN/A-2.19239Analyst DowngradeGap DownIBRXImmunityBio1.8552 of 5 stars$2.36+14.0%$12.19+416.4%-58.8%$2.08B$14.75M-2.57590News CoverageAnalyst UpgradeHigh Trading VolumeHRMYHarmony Biosciences4.7857 of 5 stars$35.65+4.7%$52.33+46.8%+19.9%$2.05B$744.85M16.90200Positive NewsTWSTTwist Bioscience4.2985 of 5 stars$32.95+6.9%$50.40+53.0%-31.1%$1.97B$347.68M-9.75990Positive NewsBLTEBelite Bio2.0489 of 5 stars$61.99+1.5%$96.67+55.9%+43.5%$1.97BN/A-55.8510News CoverageAnalyst RevisionGap Up Related Companies and Tools Related Companies DNLI Alternatives VCEL Alternatives NAMS Alternatives AAPG Alternatives KYMR Alternatives BHVN Alternatives IBRX Alternatives HRMY Alternatives TWST Alternatives BLTE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MRVI Stock Free MRVI Stock Alerts